// App-Quantinova.ai

: Utility of a Proteomic Surrogate for Cardiovascular Outcomes to Predict and Monitor COVID-19 Induced Myocarditis

Researchers

Presenter

  • Clare Paterson

Principal Investigators

  • Michael A Hinterberg

  • Andrew J Morrow

  • Robert Sykes

  • Kenneth Mangion

  • Paul Welsh

  • Alex McConnachie

  • Naveed Sattar

  • Colin Berry

  • Stephen A Williams

Medical Centers

  • British Heart Foundation (BHF) Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom

  • SomaLogic Operating Co., Inc, Boulder, CO

  • British Heart Fndn Cardiovascular Res Ctr, Univ of Glasgow, Glasgow, United Kingdom

  • Robertson Cntr for Biostatistics, Institute of Health and Wellbeing, Univ of Glasgow, Glasgow, United Kingdom

  • Clinical R&D, SomaLogic Operating Co., Inc, Boulder, CO

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Infectious Diseases (ID)

Disease

  • Viral myocarditis

  • Coronavirus disease

Biomarkers

  • Troponin I

  • N-terminal pro b-type natriuretic peptide

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved